Get the Stockscreener App
2.17
8.05%
-0.19
After Hours:
2.22
0.05
+2.30%
Cognition Therapeutics Inc stock is traded at $2.17, with a volume of 5.45M.
It is down -8.05% in the last 24 hours and up +97.27% over the past month.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
See More
Previous Close:
$2.36
Open:
$2.33
24h Volume:
5.45M
Relative Volume:
0.53
Market Cap:
$159.55M
Revenue:
-
Net Income/Loss:
$-22.83M
P/E Ratio:
-2.7468
EPS:
-0.79
Net Cash Flow:
$-20.87M
1W Performance:
-16.86%
1M Performance:
+97.27%
6M Performance:
+411.43%
1Y Performance:
+259.51%
1-Day Range:
$1.87
$2.375
1-Week Range:
$1.87
$2.60
52-Week Range:
$0.2223
$3.83
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Name
Cognition Therapeutics Inc
Sector
Industry
Phone
412-481-2210
Address
2403 SIDNEY STREET, PITTSBURGH
Compare CGTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
2.17 | 221.44M | 0 | -22.83M | -20.87M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jul-30-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-03-21 | Initiated | B. Riley Securities | Buy |
| Nov-03-21 | Initiated | Oppenheimer | Outperform |
Cognition Therapeutics Inc Stock (CGTX) Latest News
Cognition Therapeutics (NASDAQ:CGTX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
CGTX Q3 EPS Estimate Raised by Brookline Capital Management - MarketBeat
Is Cognition Therapeutics Inc. a good stock for dollar cost averagingPortfolio Value Summary & Weekly Top Performers Watchlists - Lancaster City Council
Cognition Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement - 富途牛牛
Visualizing Cognition Therapeutics Inc. stock with heatmapsPortfolio Growth Summary & Community Supported Trade Ideas - Newser
Cognition Therapeutics Regains Nasdaq Compliance - MSN
Cognition Therapeutics Inc. stock retracement – recovery analysisInsider Buying & Daily Stock Trend Watchlist - Newser
Is Cognition Therapeutics Inc. Forming a Bottom PatternMarket Sentiment Review & Weekly Momentum Stock Picks - beatles.ru
Chart overlay techniques for tracking Cognition Therapeutics Inc.2025 Stock Rankings & Scalable Portfolio Growth Ideas - Newser
Cognition Therapeutics Inc. stock prediction for this weekTreasury Yields & Daily Chart Pattern Signal Reports - Newser
Tick level data insight on Cognition Therapeutics Inc. volatilityMarket Trend Report & Fast Moving Stock Trade Plans - Newser
Can Cognition Therapeutics Inc. keep up with sector leaders2025 Bull vs Bear & Free Community Consensus Stock Picks - خودرو بانک
Neurology biopharmas rebound on trial catalysts and Q2 gains - BioWorld MedTech
What moving averages say about Cognition Therapeutics Inc.2025 Retail Activity & High Yield Stock Recommendations - Newser
Is Cognition Therapeutics Inc. a stock for growth or value investors2025 Price Targets & Low Drawdown Trading Strategies - خودرو بانک
Backtesting results for Cognition Therapeutics Inc. trading strategiesMarket Risk Report & Reliable Entry Point Trade Alerts - Newser
Published on: 2025-09-05 00:35:53 - Newser
Published on: 2025-09-05 00:14:17 - Newser
Real time pattern detection on Cognition Therapeutics Inc. stockRisk Management & Advanced Technical Signal Analysis - Newser
Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock - 富途牛牛
Support Zone Holds Steady for Cognition Therapeutics Inc. After DipMarket Weekly Review & Weekly High Conviction Ideas - Newser
Multi asset correlation models including Cognition Therapeutics Inc.Market Activity Report & Daily Profit Maximizing Trade Tips - Newser
Cognition Therapeutics Inc. stock trend forecastTrade Entry Summary & Breakout Confirmation Trade Signals - Newser
Top chart patterns to watch in Cognition Therapeutics Inc.Weekly Trend Report & Safe Capital Growth Plans - Newser
How to manage a losing position in Cognition Therapeutics Inc.Earnings Overview Report & Low Risk High Win Rate Picks - Newser
Can Cognition Therapeutics Inc. recover in the next quarter2025 Retail Activity & Daily Profit Focused Stock Screening - Newser
How sentiment analysis helps forecast Cognition Therapeutics Inc.Quarterly Growth Report & Daily Entry Point Alerts - Newser
Real time scanner hits for Cognition Therapeutics Inc. explainedTreasury Yields & Community Verified Swing Trade Signals - Newser
Cognition’s Alzheimer’s drug trial reaches 75% enrollment milestone By Investing.com - Investing.com South Africa
Cognition Therapeutics closes $30 million registered direct offering By Investing.com - Investing.com Australia
Does Cognition Therapeutics Inc. have pricing power2025 Technical Patterns & Free Real-Time Volume Trigger Notifications - khodrobank.com
Cognition’s Alzheimer’s drug trial reaches 75% enrollment milestone - Investing.com
Trend analysis for Cognition Therapeutics Inc. this weekPortfolio Update Summary & AI Powered Trade Plan Recommendations - Newser
Cognition Therapeutics, Inc. Achieves 75% Enrollment in Phase 2 START Study for Early Alzheimer’s Disease Treatment - Quiver Quantitative
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target - GlobeNewswire
540-Patient Alzheimer's Trial: Cognition's Once-Daily Oral Drug Zervimesine Reaches Major Milestone - Stock Titan
What’s next for Cognition Therapeutics Inc. stock price2025 Performance Recap & Growth-Oriented Investment Plans - Newser
MACD Cross Could Confirm Trend in Cognition Therapeutics Inc.Weekly Market Summary & AI Enhanced Trading Alerts - beatles.ru
Cognition Therapeutics shares fall 1.23% premarket after closing a $30 million registered direct offering. - AInvest
How to integrate Cognition Therapeutics Inc. into portfolio analysis toolsJuly 2025 Decliners & Advanced Technical Analysis Signals - Newser
Is Cognition Therapeutics Inc. still worth holding after the dipGold Moves & Free Safe Capital Growth Stock Tips - Newser
Cognition Therapeutics Inc. stock trend outlook and recovery pathTrade Analysis Summary & Technical Confirmation Trade Alerts - Newser
Will Cognition Therapeutics Inc. stock go up soonJuly 2025 Momentum & Short-Term Swing Trade Alerts - Newser
How to build a custom watchlist for Cognition Therapeutics Inc.2025 Dividend Review & Scalable Portfolio Growth Ideas - Newser
What to expect from Cognition Therapeutics Inc. in the next 30 daysWeekly Stock Analysis & AI Enhanced Market Trend Forecasts - Newser
Automated trading signals detected on Cognition Therapeutics Inc.Take Profit & Expert Curated Trade Setup Alerts - Newser
Is Cognition Therapeutics Inc. trading at a discountJuly 2025 Trends & Smart Money Movement Alerts - خودرو بانک
Cognition Therapeutics Closes $30 Million Direct Offering - MarketScreener
Cognition Therapeutics Inc Stock (CGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):